XTL Biopharmaceuticals Ltd. announced on November 21^st that it has
acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical
Industries Ltd. TEVA in
consideration for an amount of approximately NIS 6.5 million, which represents
an amount of NIS 1.405 per Share (approximately 22% premium). The Shares
represent all of Teva's shares in Proteologics and represent approximately
31.35% of Proteologics issued and outstanding share capital.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsAsset Sales
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in